Previous Close | 367.41 |
Open | 368.61 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1100 |
Day's Range | 365.24 - 371.05 |
52 Week Range | 205.10 - 403.44 |
Volume | |
Avg. Volume | 291,391 |
Market Cap | 17.533B |
Beta (5Y Monthly) | 0.91 |
PE Ratio (TTM) | 25.79 |
EPS (TTM) | 14.22 |
Earnings Date | Apr 25, 2024 |
Forward Dividend & Yield | 3.40 (0.93%) |
Ex-Dividend Date | Feb 15, 2024 |
1y Target Est | 414.06 |
Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
Recently, Zacks.com users have been paying close attention to Carlisle (CSL). This makes it worthwhile to examine what the stock has in store.
According to the average brokerage recommendation (ABR), one should invest in Carlisle (CSL). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?